The late acquisition of TP53 missense mutations in low-frequency subclones in the primary tumour appears to be the driver for metastasis since we detect identical TP53 mutations at high frequency in the matching metastases and furthermore can detect these mutations in the blood. The gene discussed is TP53; the disease is neoplasm.